U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. FDA Organization
  4. Office of Medical Products and Tobacco
  5. Center for Drug Evaluation and Research | CDER
  6. Office of Infectious Diseases (OID)
  1. Center for Drug Evaluation and Research | CDER

Office of Infectious Diseases (OID)

The Office of New Drugs is undergoing a reorganization. This site will be updated in the near future.  Please check back often.  For more information, please visit: Reorganization of the Office of New Drugs with Corresponding Changes to the Office of Translational Sciences and the Office of Pharmaceutical Quality. Until this page is updated, please use the current contact information presented on this page or contact druginfo@fda.hhs.gov if you have additional questions.

Mission

The Office of Infectious Diseases (OID) consists of three review divisions: The Division of Anti-Infectives (DAI), the Division of Antivirals (DAV), and the Division of Pharm/Tox for Infectious Diseases (DPT-ID). The Immediate office oversees the development, review, and regulation of applications as well as issues related to toxicology for drug and biologic products reviewed in these divisions.

Immediate Office

Director: John Farley, M.D., MPH
Deputy Director: TBD
Associate Director for Research: Thushi Amini, Ph.D.
Associate Director for Regulatory Science: Sunita Shukla, Ph.D., M.P.H.

Division of Anti-Infective (DAI)

Director: Sumathi Nambiar, M.D., M.P.H.
Deputy Director: Dmitri Iarikov, M.D., Ph.D.
Regulatory Operations Chief Project Managers: Maureen Dillon-Parker and Carmen DeBellas

Division of Antiviral (DAV)

Director: Debra Birnkrant, M.D.
Deputy Director: Jeffery Murray, M.D., M.P.H
Regulatory Operations Chief Project Manager: Karen Winestock

Division of Transplant and Ophthalmology Products (DTOP)

The Division of Ophthalmology will be part of the Office of Specialty Medicine beginning in mid-Jan 2020.  For more information, please visit: Reorganization of the Office of New Drugs with Corresponding Changes to the Office of Translational Sciences and the Office of Pharmaceutical Quality.

Director: Ozlem Belen, M.D (Acting)
Deputy Director: Wiley Chambers, M.D.

OID Research Activities

Overview of research needs, requests for information (RFIs), public workshops/meetings, opportunities for collaboration, externally awarded research studies, and other important research.

OID Regulatory Science Activities

Contact Us

Mailing Address:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Infectious Diseases
10903 New Hampshire Avenue
Silver Spring, MD 20993
Phone: (301) 796-1300
Fax: (301) 796-9887

Resources For You